Metabolic Dysfunction-Associated Steatotic Liver Disease, Type 2 Diabetes
Conditions
Keywords
Type 2 diabetes patients, metabolic dysfunction-associated steatotic liver disease
Brief summary
The investigators plan to use the smartphone App for FIB-4 calculation and increase the awareness of liver fibrosis. These patients might notify and discuss with the physician of their liver fibrosis severity to improve the identification, and management of liver fibrosis. This is to establish a patient-centered clinical pathway to identify patients with advanced fibrosis in type 2 diabetes patients. The investigators plan to conduct this randomized controlled trial of two groups: FIB-4 APP group and the standard care group. The primary end point is the referral rate of patients with advanced fibrosis (FIB-4 ≥ 2.67).
Detailed description
Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease in people with type 2 diabetes. Patients with prediabetes/type 2 diabetes or 2 or more metabolic risk factors are at higher risk for hepatic fibrosis. Type 2 diabetes increases the risk of cirrhosis, cirrhotic complications and liver-related mortality. According to the American Gastroenterology Association guideline, NAFLD screening should be considered for individuals older than 40 years with type 2 diabetes mellitus. The American diabetes association now advises screening all adults with type 2 diabetes or prediabetes, particularly those with obesity or cardiometabolic risk factors or established cardiovascular disease for clinically significant liver fibrosis (defined as moderate fibrosis to cirrhosis) using a calculated fibrosis-4 index (FIB-4), even those with normal liver enzyme levels.4 People with type 1 diabetes who have obesity, hepatic steatosis, or elevated aminotransferases should also screen for NAFLD. The recommended screening tool is the fibrosis-4 index (FIB-4), a calculation that includes the patient's age, liver enzyme levels, and platelet counts. A score of 1.3 or higher is considered high risk for clinically significant fibrosis, and above 2.67 is very high-risk. According to a recent study of 1918 patients who received screening Fibroscan, 72.8% had steatosis, and 17.1% had advanced fibrosis (Fibroscan \>= 9.6kpa). In another study in Malaysia, among 557 type 2 DM patients who received Fibroscan, 72.4% had NAFLD, and 21% had advanced fibrosis(Fibroscan \>= 9.6kpa). Another study screened 561 type 2 diabetes patients in the US, 70% had steatosis, and 9% had advanced fibrosis (Fibroscan \>= 9.7kpa). Overall, the prevalence of steatotic liver disease is 70%, and the percentage of advanced fibrosis (\>=F3) is 9-21%. However, the screening of NAFLD in type 2 diabetes patients are underutilized. Because there is still a significant knowledge gap in the clinicians for the identification, diagnosis, and management of NAFLD. There is no country had a national or subnational strategy for NAFLD. Several clinical pathways to facilitate the evaluation of NAFLD in type 2 diabetes patients are developing now. Instead of relying on active assessment by clinicians, automated fibrosis score calculation using the FIB-4 index followed by reminder messages in the electronic clinical management system increased appropriate referral for hepatology assessment or further fibrosis tests in patients with increased fibrosis scores from 3.1% to 33.3%. However, there is still more than 2/3 of patients was not referred for further fibrosis evaluation. The electronic notification system is not widely available for all clinics, while nearly every patient has the mobile phone. Applying the notification system through the smartphone APP is beneficial for the patients to participate actively for their personal health management and improving disease awareness. The investigators plan to use the smartphone App for FIB-4 calculation and increase the awareness of liver fibrosis. These patients might notify and discuss with the physician of their liver fibrosis severity to improve the identification, and management of liver fibrosis. This is to establish a patient-centered clinical pathway to identify patients with advanced fibrosis in type 2 diabetes patients. The investigators plan to conduct this randomized controlled trial of two groups: FIB-4 APP group and the standard care group. The primary end point is the referral rate of patients with advanced fibrosis (FIB-4 ≥ 2.67).
Interventions
BEHAVIORALAPP calculation for FIB-4
the investigators plan to use the smartphone App for FIB-4 calculation and notify the patients.
BEHAVIORALStandard Care (in control arm)
The standard group proceeds as regular practice
Sponsors
National Taiwan University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
35 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Type 2 diabetes patients, regular follow-up in OPD every 3 months 2. Age 35-65 (Because FIB-4 is not accurate in people with age \<35 or \> 65)
Exclusion criteria
1. Patients are regularly follow the investigators at the liver clinic for liver disease 2. Active malignancy 3. Hematology disease with thrombocytopenia 4. Pregnant patients with type 2 diabetes
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The hepatology clinic referral rate if FIB-4 ≥ 2.67 (advanced fibrosis, F3) | through study completion, an average of 1 year | Number of patients with FIB-4 ≥ 2.67 being referred to hepatology clinic, divided by total number of patients with FIB-4 ≥ 2.67. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The percentage of patients examined by Fibroscan in each group with FIB4≥2.67 | through study completion, an average of 1 year | The number of patients with a FIB-4 ≥ 2.67 and received the fibroscan test, divided by the total number of patients with a FIB-4 ≥ 2.67 |
| The hepatology clinic referral rate if FIB-4 ≥ 1.3 and <2.67 in individual groups | through study completion, an average of 1 year | The number of patients with FIB-4 ≥ 1.3 and \<2.67 and referred to the hepatology clinic, divided by the total number of patients with FIB-4 ≥ 1.3 and \<2.67 |
| Incidence rate of liver cirrhosis in individual groups | through study completion, an average of 1 year | Patients diagnosed with liver cirrhosis clinically, divided by the total number of patients in the individual group |
| The hepatology clinic referral rate of patients with FIB-4 <1.3 in individual groups | through study completion, an average of 1 year | The number of patients with FIB-4 \<1.3 and referred to hepatology clinic, divided by the total number of patients with FIB-4 \<1.3 |
Countries
Taiwan
Contacts
Primary ContactTung Hung Su, MD, PhD
Outcome results
None listed